Yang Xu

Dr. Yang Xu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2019 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
WGWenxing Gu
Wenxing Gu
JAJingnan An
Jingnan An
HMHao Meng
Hao Meng
NYNa Yu
Na Yu
YZYinan Zhong
Yinan Zhong
ZZZhiyuan Zhong
Zhiyuan Zhong

27 October 2021 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
DLDandan Lin
Dandan Lin
BHBo Hu
Bo Hu
PLPengfei Li
Pengfei Li
YZYe Zhao
Ye Zhao
YXYang Xu
Yang Xu
DWDepei Wu
Depei Wu
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most curative strategies for the treatment of many hematologic malignancies and diseases. However, acute graft-versus-host disease (GVHD) limits the success of allo-HSCT. The prevention and treatment of acute GVHD is the key issue for improving the efficacy of allo-HSCT and has become a research hotspot. The intestine is the primary organ targeted by acute GVHD, and the intestinal microbiota is critical for maintaining the homeostasis of the intestinal microenvironment and the immune response. Many studies have demonstrated the close association between the intestinal microbiota and the pathogenesis of acute GVHD. Furthermore, dysbiosis of the microbiota, which manifests as alterations in the diversity and composition of the intestinal microbiota, and alterations of microbial metabolites are pronounced in acute GVHD and associated with poor patient prognosis. The microbiota interacts with the host directly via microbial surface antigens or microbiota-derived metabolites to regulate intestinal homeostasis and the immune response. Therefore, intervention strategies targeting the intestinal microbiota, including antibiotics, prebiotics, probiotics, postbiotics and fecal microbiota transplantation (FMT), are potential new treatment options for acute GVHD. In this review, we discuss the alterations and roles of the intestinal microbiota and its metabolites in acute GVHD, as well as interventions targeting microbiota for the prevention and treatment of acute GVHD.

26 August 2023 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
NZNana Zheng
Nana Zheng
JWJiaqi Wei
Jiaqi Wei
DWDepei Wu
Depei Wu
YXYang Xu
Yang Xu
JGJIANPING GUO
JIANPING GUO

17 February 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YRYuhua Ru
Yuhua Ru
XZXiang Zhang
Xiang Zhang
TSTiemei Song
Tiemei Song
YDYiyang Ding
Yiyang Ding
ZZZiling Zhu
Ziling Zhu
DWDepei Wu
Depei Wu

20 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DJDongpeng Jiang
Dongpeng Jiang
HHHaiwen Huang
Haiwen Huang
HQHuimin Qin
Huimin Qin
KTKoukou Tang
Koukou Tang
XSXiangru Shi
Xiangru Shi
JCJianhong Chu
Jianhong Chu
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can experience BCMA antigen loss leading to relapse, thus necessitating the identification of additional CAR-T targets. Here, we show that FcRH5 is expressed on multiple myeloma cells and can be targeted with CAR-T cells. FcRH5 CAR-T cells elicited antigen-specific activation, cytokine secretion and cytotoxicity against MM cells. Moreover, FcRH5 CAR-T cells exhibited robust tumoricidal efficacy in murine xenograft models, including one deficient in BCMA expression. We also show that different forms of soluble FcRH5 can interfere with the efficacy of FcRH5 CAR-T cells. Lastly, FcRH5/BCMA-bispecific CAR-T cells efficiently recognized MM cells expressing FcRH5 and/or BCMA and displayed improved efficacy, compared with mono-specific CAR-T cells in vivo. These findings suggest that targeting FcRH5 with CAR-T cells may represent a promising therapeutic avenue for MM.

9 November 2022 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
YLYin Liu
Yin Liu
YZYe Zhao
Ye Zhao
JQJiaqian Qi
Jiaqian Qi
XMXiao Ma
Xiao Ma
XQXiaofei Qi
Xiaofei Qi
YXYang Xu
Yang Xu
Acute graft-versus-host disease (aGVHD), especially intestinal aGVHD, is one of the most severe complications after allogeneic hematopoietic stem cell transplantation (HSCT). Fecal microbiota transplantation (FMT) has been applied to the treatment of intestinal steroid-refractory aGVHD (SR-aGVHD). Ruxolitinib is the first drug recommended for SR-aGVHD. Here, we reported the outcome data from 21 patients who had received the combined treatment of FMT with ruxolitinib as a salvage treatment in intestinal SR-aGVHD after HSCT. The overall response rate on day 28 was 71.4% (95% CI 50.4–92.5%), including 10 patients with complete responses. The durable overall response at day 56 in responders was 80%. GVHD relapse rate was 33.3% in responders. The levels of inflammatory cytokines as well as T cells and NK cells activation declined. The diversity of the intestinal microbiota was improved in responders. Viral reactivations and severe cytopenia were the major adverse events (61.9% and 81% respectively). The estimated 6-month overall survival was 57.1% (95% CI: 35.9–78.3%), while event-free survival was 52.4% (95% CI: 21.7%-64.1%). Collectively, FMT with ruxolitinib could be an effective treatment for intestinal SR-aGVHD after HSCT.Trial registration: ClinicalTrials.gov identifier: NCT03148743.